Journal profile · PHARMACOLOGY & PHARMACY
GaBI Journal-Generics and Biosimilars Initiative Journal
ISSN 2033-6403 · eISSN 2033-6772 · Pro Pharma Communications International
GaBI Journal-Generics and Biosimilars Initiative Journal: CAS Zone 4 · Medicine (2025 upgraded edition); subscription journal; APC charged, amount not published; 19 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
GaBI Journal-Generics and Biosimilars Initiative Journal is published by Pro Pharma Communications International and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmaceutical Economics and Policy, Biosimilars and Bioanalytical Methods and Health Systems, Economic Evaluations, Quality of Life, together about 67.8% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
MissionThe mission of GaBI Journal is to provide an independent, high quality, authoritative, and peer reviewed platform for the publication of scientific articles concerning any aspect of the research into and development of cost-effective medicines, irrespective of their source. This Open Access journal will thus make information on pharmaceutical innovation and developments in generic and biosimilar medicines accessible to everyone, including physicians, pharmacists and nurses, patients/consumers, drug developers, third-party payers, legislators and assessors. This is achieved by: independent peer review collaboration with all relevant stakeholders (physicians/prescribers, regulatory authorities, industry, third-party payers and governments) publishing via open access channels, both in print and electronically. Scope and profileThe scope of GaBI Journal is broad and of interest and relevance to professionals active in clinical practice, pharmaceutical science and policy. Materials published in GaBI Journal include high quality research reports, literature reviews and case studies, all of which are peer reviewed. Manuscripts on all aspects of generic and biosimilar medicines, covering areas in clinical, fundamental, technical, economic and social aspects of pharmaceuticals and therapeutics are welcome. In addition, high quality work submitted in other formats, for example, scientific and evidence-based commentaries may also be considered. In all cases, the emphasis is on quality, originality and knowledge contribution to those involved in health care. All manuscripts submitted to GaBI Journal are subject to a rigorous peer review process. GaBI Journal plans to be indexed in PubMed, and that indexing will be retrospective. GaBI Journal is published quarterly. All articles are published in English. The initial circulation exceeds 5,000 copies to professionals in clinical practice and healthcare policies, pharmaceutical experts and scientists worldwide. GaBI Journal is unique as an independent, peer reviewed academic journal—it encompasses all aspects of generic and biosimilar medicines development and use, from fundamental research to clinical application and policies.
From the journal's Aims & Scope
Research area (LetPub): PHARMACOLOGY & PHARMACY
Editor-in-chief Robin ThorpePublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmaceutical Economics and PolicyEconomics, Econometrics and Finance29.6%
- Biosimilars and Bioanalytical MethodsImmunology and Microbiology29.3%
- Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance9%
- Biomedical Ethics and RegulationMedicine7.7%
- Pharmaceutical studies and practicesMedicine3.3%
- Analytical Methods in PharmaceuticalsChemistry2.6%
- Monoclonal and Polyclonal Antibodies ResearchMedicine2.2%
- Healthcare RegulationHealth Professions2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pharmacy | Q3 | 34/52 | 35th |
| Drug Guides | Q3 | 7/10 | 35th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 0.7LetPub ·
- SJR 2026-06
- 0.22LetPub ·
- SNIP 2026-06
- 0.33LetPub ·
- h-index
- 25OpenAlex ·
- i10-index
- 82OpenAlex ·
- 2-year mean citedness
- 0.67OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 534 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 1 | 0 | 80 |
| 2025 | 19 | 0 | 110 |
| 2024 | 40 | 0 | 121 |
| 2023 | 21 | 0 | 119 |
| 2022 | 21 | 1 | 175 |
| 2021 | 27 | 4 | 237 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Peer review
- Single-anonymous peer reviewPublisher website · model-extracted
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | EUR 250 | — | — |
Other charges and waivers (author guidelines)
- Other fees
- No other fees
- Page charges
- Charged; see the journal's website for the amount
- Submission fee
- EUR 250
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 3–6
- Manuscript length
- ≤ 5,300 words
- Suggested reviewers
- Required
Article types accepted12, with length limits
- brief reportCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …Length not stated
- commentaryCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …main text ≤ 1,600 words
- editorialCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …Length not stated
- letters to the editorManuscript Submission Submit Letters to the Editor Article Processing Charges Copyright Fast Track Author ResourcesLength not stated
- meta-analysisCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …Length not stated
- opinionCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …Length not stated
- original researchCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …Length not stated
- original research paperCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …main text ≤ 5,000 words
- perspective. We welcome submissions and proposals. Perspective articles are limited to 1,600 to 2,400 words and usually include one figure. There is a maximum of 20 remain text ≤ 2,400 words
- reviewCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …Length not stated
- review articleCommentary – invited article, usually a thought-provoking idea or opinion on selected topics or brief report from members of the Editorial Board, International …main text ≤ 6,500 words
- short communicationsOriginal research, review article, meta-analysis, short communications, and letters to the Editor will be considered for publication.Length not stated
Policy excerpts from the journal's websiteAuthorship, Conflicts of interest, Publication ethics, License & copyright, Peer review, Preprints
- Authorship Authorship and contributorship
Language editing service Model summary
Authorship decisions and contributor disclosures are explicit ways of assigning responsibility, giving credit for intellectual work and ensuring transparency. Most journals have adopted the ICJME guidelines, which state that author- ship credit should be based on the following criteria: Authors are those who made a significant contribution to (a) the study concept and design, acquisition of data, …
Source ↗Publisher website ·- Conflicts of interest Conflict of interest disclosure
At time of submission, the manuscript must be accompanied by the Conflict of Interest Disclosure statement which is available from the International Committee of Medical Journal Editors (ICMJE), or click here to download the Conflict of Interest Disclosure statement. Each author must disclose and describe any affiliations or financial arrangements or relationships with any company whose product ap…
Source ↗Publisher website ·- Publication ethics
ICMJE standards Model summary
GaBI Journal adheres to the standard of the International Committee of Medical Journal Editors (ICMJE) – Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication, see www.ICMJE.org.
Source ↗Publisher website ·- License & copyright Copyright
Copyright transfer Model summary
It is a condition of publication that manuscripts submitted to GaBI Journal have not been and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publisher if and when the article is accepted for publication. The authors are required to sign a ‘Copyright Transfer’ form at time of manusc…
Source ↗Publisher website ·- Peer review Peer Review
Peer review process Model summary
All manuscripts submitted to GaBI Journal are subject to a rigorous peer review process. We welcome suggestions for referees from the author though these recommendations may or may not be used. Names, postal and email addresses of three to four experts in the appropriate area of research should accompany each manuscript submission. Read more →
Source ↗Publisher website ·- Preprints
Ahead of print publication Model summary
All articles are published electronically ahead of print with the definite citation line.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Pro Pharma Communications International
- ISSN
- 2033-6403
- Electronic ISSN
- 2033-6772
- Latest issue on the website
- Volume 15, Issue 1 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Special issues ↗Publisher website
FAQ
Frequently asked questions about GaBI Journal-Generics and Biosimilars Initiative Journal
What CAS zone is GaBI Journal-Generics and Biosimilars Initiative Journal in?
In the 2025 upgraded edition of the CAS Journal Ranking, GaBI Journal-Generics and Biosimilars Initiative Journal is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What are the manuscript requirements of GaBI Journal-Generics and Biosimilars Initiative Journal?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 3–6; Manuscript length: ≤ 5,300 words; Suggested reviewers: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Which databases index GaBI Journal-Generics and Biosimilars Initiative Journal?
According to LetPub and DOAJ records, GaBI Journal-Generics and Biosimilars Initiative Journal is indexed in ESCI and Scopus. The journal's website also lists PubMed; that list has not been checked against each database.
Is GaBI Journal-Generics and Biosimilars Initiative Journal open access, and what is the APC?
GaBI Journal-Generics and Biosimilars Initiative Journal is a subscription journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .